Frequently Asked Questions Which is stronger, Sermorelin or CJC-1295/Ipamorelin
Collectively, GLP-1 RAs reduced the risks of MACE, composite cardiovascular outcomes, CVD events, and cardiovascular mortality (Class IIIIV
Instead of focusing only on short-term tolerability, providers should evaluate the longer trajectory of gastrointestinal effects
This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 6 print issues and online access 251,40 per year only 41,90 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF
staggered titration Cycle driver GI tolerance sets the pace Tirzepatide Loading 2.5 5 7.5 10 12.5 mg (every 4 weeks) Frequency Once weekly Maintenance 15 mg weekly Route SubQ Cagrilintide Loading Start Week 9: 0.25 0.5 1.0 1.7 mg Frequency Once weekly Maintenance 2.4 mg weekly Route SubQ Weekly Schedule Example (Maintenance Phase) Monday Tirzepatide 15 mg (one site) + Cagrilintide 2.4 mg (different site) Tuesday No injections Wednesday No injections Thursday No injections Friday No injections Saturday No injections Sunday No injections Both compounds are once weekly